Family of NLRP3 inhibitors is differentiated by novel structure, central nervous system penetration, and potential for improved safety and efficacy
RICHMOND, Calif.–(BUSINESS WIRE)–#aging–BioAge Labs, Inc. (“BioAge”), a privately held clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced that it will present updates on its NLRP3 inhibitor program [link] at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany. BioAge is developing its novel, proprietary class of NLRP3 inhibitors, which have distinct structural and biological properties and include molecules that penetrate the blood–brain barrier, for neurodegenerative and neurosensory disorders associated with aging.
“Our family of potent, structurally differentiated NLRP3 inhibitors demonstrates BioAge’s capability to discover novel compounds for promising targets emerging from our discovery platform,” said BioAge CEO and co-founder Kristen Fortney, PhD. “I am excited about the potential of these drugs to treat diseases driven by brain aging, and our team is looking forward to the opportunity to share recent data from this program at multiple important scientific gatherings.”
At the inaugural Neurodegeneration Targets meeting hosted by Cambridge Healthtech Institute [link], Rusty Montgomery, PhD, Vice President, Biology, will deliver a talk titled “Identification of a Novel Class of Highly Potent, CNS-Penetrant NLRP3-Specific Inhibitors with Excellent Drug-Like Physical Features” in Boston, MA on Oct. 20, 2022. Kevin Willhelmsen, PhD, Associate Director of Immunology, will present on the same topic at the Inflammasome Therapeutics Summit [link] in Boston on Nov. 29, 2022.
In addition, at BIO-Europe [link], Peng Leong, PhD, MBA, Chief Business Officer and Head of Brain Aging at BioAge, will speak on a panel titled “Immuno-inflammation: A Gateway to Therapeutic Areas and New Partners” on Oct. 24, 2022. He will be joined by panelists Vishal Sahni, Director, Corporate Business Development and Strategy at H. Lundbeck A/S; Duncan Emmerton, Executive Director, Pharma Intelligence; and Andrew Mackie, Chief Business Officer, Imcyse.
“The BioAge target discovery platform revealed that NLRP3 activity is correlated with mortality and cognitive decline,” Leong said, “Inhibition of NLRP3 and other mediators of chronic inflammation identified by our platform has the potential to prevent multiple age-related disorders driven by pathologic inflammation.”
Leong will be available at BIO-Europe for potential partnership discussions. Attendees can send meeting requests to BioAge via the contact information in this release.
About BioAge Labs, Inc.
BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records to map out the key molecular pathways that impact healthy human aging. By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat or even prevent age-related disease in entirely new ways. BioAge currently has multiple clinical-stage programs in its growing portfolio targeting muscle, immune, and brain aging. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. For additional information about BioAge, visit the company’s website at https://www.bioagelabs.com.